The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Imigran 20 mg Nasal Spray, Solution



GlaxoSmithKline (Ireland) LimitedPA1077/008/004

Main Information

Trade NameImigran 20 mg Nasal Spray, Solution
Active SubstancesSumatriptan
Dosage FormNasal spray, solution
Licence HolderGlaxoSmithKline (Ireland) Limited
Licence NumberPA1077/008/004

Group Information

ATC CodeN02CC Selective serotonin (5HT1) agonists
N02CC01 sumatriptan

Status

License statusAuthorised
Licence Issued07/07/1999
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back